These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27340673)

  • 81. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician.
    Moingeon P
    J Allergy Clin Immunol Pract; 2013; 1(3):228-41. PubMed ID: 24565479
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A High Proportion of Canadian Allergists Offer Oral Immunotherapy but Barriers Remain.
    Mack DP; Soller L; Chan ES; Hanna MA; Terpstra C; Vander Leek TK; Bégin P
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1902-1908. PubMed ID: 33359585
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Biologics in practice: A unique opportunity for allergist/immunologist expertise.
    Katial RK
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):105-7. PubMed ID: 27499536
    [No Abstract]   [Full Text] [Related]  

  • 84. Shifts in allergy practice in a COVID-19 world: Implications of pre-COVID-19 national health care provider and patient surveys of treatments for nasal allergies.
    Winders T; DuBuske L; Bukstein DA; Meltzer EO; Wallace D; Rance K
    Allergy Asthma Proc; 2021 Jul; 42(4):301-309. PubMed ID: 34030767
    [No Abstract]   [Full Text] [Related]  

  • 85. Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from
    Canonica GW; Devillier P; Casale T; Demoly P; Bos C; Karagiannis E; Passalacqua G; Wahn U; Mascarell L
    Expert Rev Clin Immunol; 2019 Sep; 15(9):921-928. PubMed ID: 31403823
    [No Abstract]   [Full Text] [Related]  

  • 86. DC-targeted gold nanoparticles as an efficient and biocompatible carrier for modulating allergic responses in sublingual immunotherapy.
    Sadeghi M; Koushki K; Mashayekhi K; Ayati SH; Keshavarz Shahbaz S; Moghadam M; Sankian M
    Int Immunopharmacol; 2020 Sep; 86():106690. PubMed ID: 32585607
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy.
    Ozdemir C; Kucuksezer UC; Akdis M; Akdis CA
    Immunol Allergy Clin North Am; 2016 Feb; 36(1):71-86. PubMed ID: 26617228
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Research progress on intralymphatic immunotherapy].
    Rong LJ; Zheng J; Lang JQ; Meng CD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Aug; 53(8):628-630. PubMed ID: 30122005
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Delving into the unknown in rhinology and allergy.
    Zanation AM
    Am J Rhinol Allergy; 2017 Jan; 31(1):1-2. PubMed ID: 28234136
    [No Abstract]   [Full Text] [Related]  

  • 90. Sublingual immunotherapy for aeroallergens: status in the United States.
    Cox L
    Allergy Asthma Proc; 2014; 35(1):34-42. PubMed ID: 24433595
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy.
    Mitobe Y; Yokomoto Y; Ohashi-Doi K
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):529-40. PubMed ID: 25701184
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy.
    Lawrence MG; Steinke JW; Borish L
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):138-42. PubMed ID: 27499541
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Sublingual Swelling due to Sublingual Immunotherapy.
    Okumura J; Hashimoto N; Hasegawa Y
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1032-1033. PubMed ID: 30292710
    [No Abstract]   [Full Text] [Related]  

  • 94. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sublingual specific immunotherapy.
    Mösges R; El Hassan E; Passàli D
    Discov Med; 2010 Oct; 10(53):348-54. PubMed ID: 21034676
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Odactra--sublingual immunotherapy for house dust mite-induced allergic rhinitis.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):37-39. PubMed ID: 29485977
    [No Abstract]   [Full Text] [Related]  

  • 97. Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit?
    Cox LS
    JAMA; 2017 Feb; 317(6):591-593. PubMed ID: 28196239
    [No Abstract]   [Full Text] [Related]  

  • 98. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 'Well days' after sublingual immunotherapy with a high-dose 6-grass pollen preparation.
    Worm M
    Allergy; 2009 Jul; 64(7):1104-5. PubMed ID: 19385951
    [No Abstract]   [Full Text] [Related]  

  • 100. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.
    Calderón MA; Cox L; Casale TB; Moingeon P; Demoly P
    J Allergy Clin Immunol; 2012 Apr; 129(4):929-34. PubMed ID: 22244595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.